Innovent Reports the First Patient Dosing of IBI333 in P-I Clinical Study for Neovascular Age-Related Macular Degeneration

Shots:

The first participant has been dosed in the P-I trial of IBI333, a recombinant anti-VEGF–A and anti-VEGF-C bispecific fusion protein in patients with nAMD
The trial focuses to evaluate the safety and tolerability of IBI333 (IVT) in patients with nAMD & will provide more encouraging innovative therapies to the clinic & benefit nAMD patients. In preclinical studies, IBI333 has proven effective at preventing angiogenesis and vascular leakage and has exhibited a dose-dependent efficacy
IBI333 is a recombinant anti-VEGF-A and anti-VEGF-C bispecific fusion protein that has been developed by Innovent. The therapy is designed to bind and neutralize the activities of VEGF-A and VEGF-C

Ref: PRNewswire  | Image: Innovent

Related News:- Innovent Reports the First Patients Dosing of Mazdutide (IBI362) in the P-III Study (DREAMS-2) for Type 2 Diabetes